ClinicalTrials.gg
CompletedNCT02649478Updated Jan 23, 2018

Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate

An interventional study of Fluticasone / Salmeterol and Placebo in Asthma, sponsored by Roxane Laboratories. Completed at 100 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2018-01-23.

Sponsored by Roxane Laboratories (part of Hikma Pharmaceuticals) · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,430
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.

Enrollment
6th of 146
1,430 · median 100
Started
2014
with 8 others
No phase
13 of 147
none open now
Registered
120th of 147
by date

Among the 147 studies testing fluticasone in Asthma, this one is the 6th largest by enrollment of the 146 interventional ones that give a count, is one of 9 that started in 2014, is one of 13 with no phase, and was the 120th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies testing fluticasone in Asthma, or all of them as a file.
02

Study summary

A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared with Advair Diskus® 100/50 in Subjects with Asthma

Read the detailed description

The primary objective of this study is to evaluate the clinical bioequivalence of generic fluticasone propionate 100 µg and salmeterol xinafoate 50 µg inhalation powder (test) to Advair Diskus ("Advair") 100/50 (reference) for the treatment of asthma.

The secondary objectives of the study are:

  • To demonstrate statistical superiority of generic fluticasone propionate 100 µg and salmeterol xinafoate 50 µg inhalation powder to placebo.
  • To demonstrate statistical superiority of Advair 100/50 to placebo.
  • To investigate the safety and tolerability of fluticasone propionate 100 µg and salmeterol xinafoate 50 µg inhalation powder compared with Advair 100/50 in the target population.
03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female subjects must be 12 years of age or older. Females must be of non- or if of childbearing potential, must commit to consistent use of a form of which is medically effective.
  2. Be able to provide written or, in the case of adolescents, informed assent in addition to an informed consent form signed by the adolescent's parent(s) or legal guardian(s).
  3. Be current non-smokers and also may not have used tobacco products (e.g., cigarettes, cigars, pipe tobacco) within the year prior to Visit 1, and have 10 years or less (10 pack-years for cigarettes) of historical use.
  4. Have persistent asthma, as defined by the National Asthma Education and Prevention Program, for at least 12 weeks before Visit 1.
  5. The forced expiratory volume at one second ("") range required for enrollment is dependent on whether the subject is an adult or adolescent and whether he or she is currently treated with inhaled ("ICS") at Visit 1
  6. Demonstrate 15% or greater reversibility of FEV1 between 10 and 30 minutes following 360 µg of albuterol inhalation. NOTE: If the subject does not meet criterion 6 at Visit 1 (Day -14), this criterion must be met at Visit 2 (Day -1).
  7. Be able to discontinue controller asthma medication (including leukotriene modifiers ("LTM"), ICS and long acting β-agonists (LABAs)) during the Run-in Period and Treatment Period.
  8. Be able to replace current short-acting β-agonists (SABAs) with the study-supplied albuterol (or equivalent) rescue medication inhaler for use as needed for the duration of the study (subjects should be able to withhold all inhaled SABAs for a least 6 hours before lung function assessments during study visits).
  9. Be appropriately using 1 of the following asthma-treatment regimens and meet the associated criteria:

    • Low- to medium-dose ICS for at least 4 weeks before Visit 1, with or without an adjunctive asthma therapy (i.e., LABA, LTM, or theophylline). Both the ICS dose and overall daily asthma regimen must have been stable for the 4 weeks before Visit 1; or
    • Leukotriene modifier (such as montelukast, zafirlukast, or pranlukast) or theophylline as monotherapy at a stable dose for at least 4 weeks before Visit 1;or
    • Daily (or near daily) rescue medication (e.g., albuterol/ salbutamol or other inhaled SABA used to treat acute asthma) in the 4 weeks before Visit 1.
  10. Must not have been treated (for any reason) with oral or parenteral corticosteroids for at least 1 month before Visit 1 and must not have used oral SABAs for at least 12 hours before Visit 1 and for the remainder of the study. Routine use of oral/parenteral corticosteroids and oral SABAs is not allowed after Visit 1.
  11. Subjects may continue using short-acting forms of theophylline (withheld at least 12 hours before a site visit), twice daily controlled release forms of theophylline (withheld at least 24 hours before a site visit), and once daily controlled-release forms of theophylline (withheld at least 36 hours before a site visit).
  12. Be able to answer questions regarding asthma status and be able to document) device usage and asthma status on a twice daily basis.

    NOTE: Placebo inhaler use (i.e., compliance) must be at least 75% of the planned doses taken as assessed at Visit 2, for the subject to be considered eligible to continue in the study.

  13. Demonstrate proper use of metered dose inhaler ("MDI") and dry-powder inhaler devices.

Exclusion criteria

Exclusion Criteria:

  1. Have an Asthma Control Questionnaire (ACQ) score of 3.0 or greater at Visit 1.
  2. Are unable to discontinue ICS, LABA, or LTM.
  3. Have a history of life-threatening asthma, defined as an asthma episode (at any time in the past) associated with any of the following: respiratory arrest or intubation, hypercapnia, hypoxic seizures, or syncopal episode.
  4. Have exercise-induced asthma as the only asthma-related diagnosis that does not require daily asthma control medicine.
  5. Have evidence or history of disease or abnormality including congestive heart failure, uncontrolled hypertension, uncontrolled coronary artery disease, myocardial infarction, or cardiac dysrhythmia. In addition, historical or current evidence of significant hematologic, hepatic, neurologic, psychiatric, renal, or other diseases that in the opinion of the investigator, would put the subject at risk through study participation, or would affect the study analyses if the disease exacerbated during the study.
  6. Have current clinical evidence of pneumonia, pneumothorax, atelectasis, pulmonary fibrotic disease, allergic bronchopulmonary aspergillosis, cystic fibrosis, bronchopulmonary dysplasia, , or other respiratory abnormalities other than asthma.
  7. Have obstructive sleep apnea severe enough to require biphasic or continuous positive-airway pressure therapy, or likely to interfere with the assessment of asthma symptoms, in the investigator's judgment.
  8. Using medication with the potential to affect the course of asthma or interact with sympathomimetic amines (e.g., β blockers [including eye drops], oral decongestants, benzodiazepines, digitalis, phenothiazines, polycyclic antidepressants, monoamine oxidase inhibitors).
  9. Had a viral or bacterial, upper or lower respiratory tract infection or sinus or middle ear infection within 4 weeks before Visit 1 or have an infection during the Run-in Period.
  10. Participated in an interventional study or used any drug for any disease within 30 days (or 4 half lives, if this is longer than 30 days) before Visit 1 before Visit 1.
  11. Used an anti-immunoglobulin E (e.g., omalizumab) or any other monoclonal antibody for any reason within 6 months before Visit 1.
  12. Are hypersensitive to any β2-agonist sympathomimetic drug, or any intranasal, inhaled, or systemic therapy or any component of these combination medications including severe milk protein .
  13. Are exhibiting any factors (e.g., infirmity, disability, or geographic location, inability to follow instructions or study compliance requirements) that the investigator believes would likely limit the subject's compliance with the study protocol or scheduled site visits. This includes recent history of substance abuse or uncontrolled psychiatric or neurological behavior that would render the subject incapable of reliably following study requirements, in the judgment of the investigator.
  14. Have an affiliation with the participating site; in other words, subject may not be an immediate family member of any study site staff and may not be employed directly or indirectly by the study site.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,430 participants (actual)

Study arms

  • Experimental
    Fluticasone / Salmeterol

    fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Vectura lever operated multidose inhaler ("LOMI") inhaler device twice a day by inhalation throughout the study

    Drug: Fluticasone / Salmeterol

  • Active comparator
    Advair Diskus 100/50

    Advair Diskus (fluticasone propionate and salmeterol xinafoate) twice a day by inhalation throughout the study

    Drug: Advair Diskus 100/50

  • Placebo comparator
    placebo inhaler

    placebo inhaled powder twice a day by inhalation throughout the study

    Drug: Placebo

Interventions

  • DrugFluticasone / Salmeterol

    Drug pages: Fluticasone · Salmeterol Xinafoate

    Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Vectura LOMI inhaler device

  • DrugPlacebo
  • DrugAdvair Diskus 100/50

    Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate administered via the Diskus inhaler device)

06

What researchers measure

Primary outcomes

  1. Baseline-adjusted area under the serial FEV1-time curve from time 0 to 12 hours on the first day of the Treatment Period

    Time frame: 0-12 hours after dosing on Day 1

  2. Baseline-adjusted, pre-dose FEV1 on the last day of the Treatment Period

    Time frame: 30 Days

Secondary outcomes

  1. Adverse Events

    Time frame: From Visit 1 (Day -28) until 30 days after the last dose of study drug

07

Study locations

100 sites
  • Roxane Laboratories Research Site #30
    Glendale, Arizona 85306, United States
  • Roxane Laboratories Research Site #46
    Phoenix, Arizona 85018, United States
  • Roxane Laboratories Research Site #1
    Surprise, Arizona 85374, United States
  • Roxane Laboratories Research Site #13
    Tempe, Arizona 85283, United States
  • Roxane Laboratories Research Site #84
    Bakersfield, California 93301, United States
  • Roxane Laboratories Research Site #72
    Costa Mesa, California 92626, United States
  • Roxane Laboratories Research Site #67
    Encinitas, California 92024, United States
  • Roxane Laboratories Research Site #4
    Fountain Valley, California 90708, United States
  • Roxane Laboratories Research Site #64
    Fullerton, California 92835, United States
  • Roxane Laboratories Research Site #3
    Huntington Beach, California 92647, United States
  • Roxane Laboratories Research Site #70
    Huntington Beach, California 92647, United States
  • Roxane Laboratories Research Site #92
    Huntington Beach, California 92647, United States
  • Roxane Laboratories Research Site #38
    Irvine, California 92614, United States
  • Roxane Laboratories Research Site #91
    Lincoln, California 95648, United States
  • Roxane Laboratories Research Site #59
    Los Angeles, California 90017, United States
  • Roxane Laboratories Research Site #16
    Los Angeles, California 90025, United States
  • Roxane Laboratories Research Site #90
    Los Angeles, California 90048, United States
  • Roxane Laboratories Research Site #6
    Mission Viejo, California 92691, United States
  • Roxane Laboratories Research Site #78
    Rolling Hills Estates, California 90274, United States
  • Roxane Laboratories Research Site #98
    Sacramento, California 95821, United States
  • Roxane Laboratories Research Site #53
    San Diego, California 92103, United States
  • Roxane Laboratories Research Site #93
    San Diego, California 92123, United States
  • Roxane Laboratories Research Site #28
    San Jose, California 95117, United States
  • Roxane Laboratories Research Site #60
    Santa Monica, California 90404, United States
  • Roxane Laboratories Research Site #33
    Centennial, Colorado 80112, United States
  • Roxane Laboratories Research Site #43
    Denver, Colorado 80246, United States
  • Roxane Laboratories Research Site #63
    Denver, Colorado 80246, United States
  • Roxane Laboratories Research Site #21
    Wheat Ridge, Colorado 80033, United States
  • Roxane Laboratories Research Site #50
    Hialeah, Florida 33012, United States
  • Roxane Laboratories Research Site #11
    Hialeah, Florida 33016, United States
  • Roxane Laboratories Research Site #66
    Homestead, Florida 33030, United States
  • Roxane Laboratories Research Site #83
    Jupiter, Florida 33458, United States
  • Roxane Laboratories Research Site #8
    Miami, Florida 33126, United States
  • Roxane Laboratories Research Site #23
    Miami, Florida 33135, United States
  • Roxane Laboratories Research Site #86
    Miami, Florida 33144, United States
  • Roxane Laboratories Research Site #89
    Miami, Florida 33144, United States
  • Roxane Laboratories Research Site #20
    Miami, Florida 33155, United States
  • Roxane Laboratories Research Site #68
    Miami, Florida 33165, United States
  • Roxane Laboratories Research Site #80
    Miami, Florida 33173, United States
  • Roxane Laboratories Research Site #54
    Miami, Florida 33174, United States
  • Roxane Laboratories Research Site #12
    Miami, Florida 33185, United States
  • Roxane Laboratories Research Site #74
    North Miami Beach, Florida 33162, United States
  • Roxane Laboratories Research Site #35
    Orlando, Florida 32806, United States
  • Roxane Laboratories Research Site #17
    Orlando, Florida 32825, United States
  • Roxane Laboratories Research Site #94
    Port Orange, Florida 32127, United States
  • Roxane Laboratories Research Site #34
    Lilburn, Georgia 30047, United States
  • Roxane Laboratories Research Site #51
    Rincon, Georgia 31326, United States
  • Roxane Laboratories Research Site #79
    Normal, Illinois 61761, United States
  • Roxane Laboratories Research Site #47
    River Forest, Illinois 60305, United States
  • Roxane Laboratories Research Site #100
    Brownsburg, Indiana 46112, United States
  • Roxane Laboratories Research Site #62
    Baltimore, Maryland 21225, United States
  • Roxane Laboratories Research Site #52
    Baltimore, Maryland 21236, United States
  • Roxane Laboratories Research Site #71
    Bethesda, Maryland 20814, United States
  • Roxane Laboratories Research Site #96
    Silver Spring, Maryland 20902, United States
  • Roxane Laboratories Research Site #81
    Fall River, Massachusetts 02720, United States
  • Roxane Laboratories Research Site #56
    North Dartmouth, Massachusetts 02747, United States
  • Roxane Laboratories Research Site #55
    Ann Arbor, Michigan 48106, United States
  • Roxane Laboratories Research Site #97
    Chelsea, Michigan 48118, United States
  • Roxane Laboratories Research Site #5
    Plymouth, Minnesota 55441, United States
  • Roxane Laboratories Research Site #85
    Saint Louis, Missouri 63141, United States
  • Roxane Laboratories Research Site #32
    Bellevue, Nebraska 68005, United States
  • Roxane Laboratories Research Site #25
    Bellevue, Nebraska 68123, United States
  • Roxane Laboratories Research Site #36
    Omaha, Nebraska 68114, United States
  • Roxane Laboratories Research Site #57
    Las Vegas, Nevada 89119, United States
  • Roxane Laboratories Research Site #10
    Atco, New Jersey 08004, United States
  • Roxane Laboratories Research Site #65
    Skillman, New Jersey 08558, United States
  • Roxane Laboratories Research Site #7
    New York, New York 10018, United States
  • Roxane Laboratories Research Site #2
    New York, New York 10019, United States
  • Roxane Laboratories Research Site #41
    Clemmons, North Carolina 27012, United States
  • Roxane Laboratories Research Site #45
    Raleigh, North Carolina 27607, United States
  • Roxane Laboratories Research Site #31
    Cincinnati, Ohio 45242, United States
  • Roxane Laboratories Research Site #95
    Columbus, Ohio 43214, United States
  • Roxane Laboratories Research Site #24
    Hilliard, Ohio 43026, United States
  • Roxane Laboratories Research Site #61
    Middleburg Heights, Ohio 44130, United States
  • Roxane Laboratories Research Site #73
    Toledo, Ohio 43617, United States
  • Roxane Laboratories Research Site #14
    Edmond, Oklahoma 73034, United States
  • Roxane Laboratories Research Site #15
    Oklahoma City, Oklahoma 73103, United States
  • Roxane Laboratories Research Site #37
    Eugene, Oregon 97401, United States
  • Roxane Laboratories Research Site #40
    Medford, Oregon 97504, United States
  • Roxane Laboratories Research Site #58
    Portland, Oregon 97202, United States
  • Roxane Laboratories Research Site #26
    Warwick, Rhode Island 02886, United States
  • Roxane Laboratories Research Site #99
    Warwick, Rhode Island 02886, United States
  • Roxane Laboratories Research Site #69
    Greenville, South Carolina 29615, United States
  • Roxane Laboratories Research Site #22
    Spartanburg, South Carolina 29303, United States
  • Roxane Laboratories Research Site #19
    Smyrna, Tennessee 37167, United States
  • Roxane Laboratories Research Site #27
    Boerne, Texas 78006, United States
  • Roxane Laboratories Research Site #75
    Dallas, Texas 75231, United States
  • Roxane Laboratories Research Site #49
    El Paso, Texas 79903, United States
  • Roxane Laboratories Research Site #44
    Houston, Texas 77043, United States
  • Roxane Laboratories Research Site #77
    Lewisville, Texas 75067, United States
  • Roxane Laboratories Research Site #87
    Plano, Texas 75093, United States
  • Roxane Laboratories Research Site #29
    San Antonio, Texas 78251, United States
  • Roxane Laboratories Research Site #48
    San Antonio, Texas 78258, United States
  • Roxane Laboratories Research Site #42
    West Jordan, Utah 84088, United States
  • Roxane Laboratories Research Site #39
    South Burlington, Vermont 05403, United States
  • Roxane Laboratories Research Site #9
    Henrico, Virginia 23233, United States
  • Roxane Laboratories Research Site #88
    Richmond, Virginia 23220, United States
  • Roxane Laboratories Research Site #18
    Richmond, Virginia 23235, United States
  • Roxane Laboratories Research Site #76
    Tacoma, Washington 98405, United States
  • Roxane Laboratories Research Site #82
    Greenfield, Wisconsin 53228, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2014, a primary completion of Nov 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2016
First posted
Jan 7, 2016
Start
Aug 2014
Primary completionActual
Nov 2015
CompletionActual
Nov 2015
Last update
Jan 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02649478
Collaborators
Vectura Limited
Responsible party
Sponsor
First posted
Jan 7, 2016
Start date
Aug 2014
Primary completion
Nov 2015
Completion
Nov 2015
Last update
Jan 23, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluticasone · Salmeterol Xinafoate

Start the discussion